Ensign Peak Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History

Ensign Peak Advisors’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-96,746	Closed	-$2.4M	–	2382
2022 Q2	$2.4M	Buy	96,746 +23,783	+33%	+$524K	0.01%	744
2022 Q1	$1.83M	Hold	72,963	–	–	﹤0.01%	925
2021 Q4	$2.66M	Buy	+72,963	New	+$2.56M	0.01%	868
2021 Q2	–	Sell	-37,224	Closed	-$1.91M	–	1868
2021 Q1	$1.91M	Hold	37,224	–	–	﹤0.01%	1139
2020 Q4	$2.31M	Hold	37,224	–	–	0.01%	980
2020 Q3	$2.04M	Buy	37,224 +22,540	+154%	+$1.21M	0.01%	961
2020 Q2	$845K	Buy	14,684 +3,058	+26%	+$166K	﹤0.01%	1331
2020 Q1	$467K	Buy	11,626 +7,929	+214%	+$337K	﹤0.01%	1408
2019 Q4	$146K	Buy	+3,697	New	+$64.9K	﹤0.01%	1632

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Ensign Peak Advisors's CCXI Position: Q3 2022 in Review

Ensign Peak Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 96,746 shares — an estimated $2.4M sold.

Ensign Peak Advisors first reported a position in CCXI in Q4 2019 and held it in 9 quarters. The position peaked at $2.66M in Q4 2021. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

Ensign Peak Advisors reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
Ensign Peak Advisors sold 96,746 ChemoCentryx, Inc. shares in Q3 2022, an estimated $2.4M.
Ensign Peak Advisors first reported a position in ChemoCentryx, Inc. in Q4 2019 and held it in 9 quarters.
Ensign Peak Advisors's ChemoCentryx, Inc. position peaked at $2.66M in Q4 2021.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.